REVA Medical Inc. Announces Completion Of Rezolve2 Clinical Enrollment And Upcoming Presentation At J.P. Morgan Conference
1/14/2014 9:24:35 AM
SAN DIEGO, Jan. 13, 2014 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that it has completed enrollment in the clinical trial of the ReZolve2 drug-eluting bioresorbable scaffold. A total of 112 patients have been enrolled in the trial to provide the data needed to apply for European CE Marking. The Company anticipates that it will file the CE Mark application before the end of 2014, as previously announced.
Help employers find you! Check out all the jobs and post your resume.
comments powered by